177990-33-9

Basic information

• Product Name: Benzyl N-Boc-4-piperidinecarboxylate
• Synonyms: Benzyl N-Boc-4-piperidinecarboxylate;1,4-Piperidinedicarboxylic acid 1-(1,1-dimethylethyl) 4-(phenylmethyl) ester;4-O-benzyl 1-O-tert-butyl piperidine-1,4-dicarboxylate
• CAS NO: 177990-33-9
• Molecular Formula: C₁₈H₂₅NO₄
• Molecular Weight: 319
• Mol File: 177990-33-9.mol

Chemical Properties

• Boiling Point: 415.5±38.0 °C(Predicted)
• Appearance: /
• Density: 1.128±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -2.31±0.40(Predicted)
• CAS DataBase Reference: Benzyl N-Boc-4-piperidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl N-Boc-4-piperidinecarboxylate(177990-33-9)
• EPA Substance Registry System: Benzyl N-Boc-4-piperidinecarboxylate(177990-33-9)

Safety Data

• Hazardous Substances Data: 177990-33-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzyl N-Boc-4-piperidinecarboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be selectively deprotected, revealing the piperidine backbone which is a common structural element in many drugs. This feature allows for the creation of a wide range of medicinal compounds with different therapeutic properties.
Used in Agrochemical Development:
In the agrochemical industry, Benzyl N-Boc-4-piperidinecarboxylate is utilized as a reagent in the synthesis of bioactive compounds, contributing to the development of new pesticides, herbicides, and other agricultural chemicals. Its versatility in organic synthesis aids in the production of effective and targeted agrochemicals.
Used in Organic Synthesis:
Benzyl N-Boc-4-piperidinecarboxylate is employed as a reagent in organic synthesis for its capacity to participate in various chemical reactions, including the formation of amide bonds and other functional group transformations. Its presence allows for the creation of complex organic molecules with specific properties for use in research and industry.

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 280115-99-3 tert-butyl 4-(chlorocarbonyl)-piperidine-1-carboxylate 
• 498-94-2 isonipecotic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 100-44-7 benzyl chloride 

Downstream Products

• 336190-98-8 benzyl 1-(3-ethoxy-3-oxopropanoyl)-4-piperidine carboxylate 
• 296240-48-7 benzyl 1-tert-butoxycarbonyl-4-methyl-4-piperidinecarboxylate 
• 951744-79-9 4-benzyloxycarbonyl-1-tert-butoxycarbonyl-4-piperidinecarboxylic acid 
• 1334679-08-1 4-(4-methoxycarbonyl-benzyl)-piperidine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester 
• 1334678-31-7 1-(2-(S)-amino-3-thiophen-2-yl-propionyl)-4-(4-dimethylcarbamoyl-benzyl)-piperidine-4-carboxylic acid cyclohexylamide hydrochloride 
• 1334679-09-2 4-(4-methoxycarbonyl-benzyl)-piperidine-1,4-dicarboxylic acid mono-tert-butyl ester 
• 1334679-11-6 4-(4-cyclohexylcarbamoyl-piperidin-4-ylmethyl)-benzoic acid methyl ester 
• 1334679-12-7 4-cyclohexylcarbamoyl-4-(4-methoxycarbonyl-benzyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1334679-13-8 4-[1-(2-(S)-tert-butoxycarbonylamino-3-thiophen-2-yl-propionyl)-4-cyclohexylcarbamoyl-piperidin-4-ylmethyl]-benzoic acid methyl ester 
• 1334679-14-9 4-[1-(2-(S)-tert-butoxycarbonylamino-3-thiophen-2-yl-propionyl)-4-cyclohexylcarbamoyl-piperidin-4-ylmethyl]-benzoic acid 
• 1310382-25-2 benzyl 1-(2-tert-butoxy-2-oxoethyl)piperidine-4-carboxylate 
• 951744-87-9 benzyl 1-tert-butoxycarbonyl-4-carbamoyl-4-piperidinecarboxylate 
• 951744-99-3 benzyl 1-tert-butoxycarbonyl-4-thiocarbamoyl-4-piperidinecarboxylate 
• 951744-80-2 (1,2-bis(4-methoxyphenyl)-2-oxoethyl) 4-benzyloxycarbonyl-1-tert-butoxycarbonyl-4-piperidinecarboxylate 

Relevant articles and documents

ANTIBACTERIAL ANTISENSE AGENTS

The invention relates to improved ANTISENSE agents for the treatment of gram-negative bacterial infections. Compounds of the invention utilise an Antibiotic-Assisted Translocation; AAT' platform to improve influx into bacterial cells through enhanced permeability, providing improved intracellular exposure of the ANTISENSE AGENT and superior treatment of the infection.

Antimalarial Inhibitors Targeting Serine Hydroxymethyltransferase (SHMT) with in Vivo Efficacy and Analysis of their Binding Mode Based on X-ray Cocrystal Structures

Target-based approaches toward new antimalarial treatments are highly valuable to prevent resistance development. We report several series of pyrazolopyran-based inhibitors targeting the enzyme serine hydroxymethyltransferase (SHMT), designed to improve microsomal metabolic stability and to identify suitable candidates for in vivo efficacy evaluation. The best ligands inhibited Plasmodium falciparum (Pf) and Arabidopsis thaliana (At) SHMT in target assays and PfNF54 strains in cell-based assays with values in the low nanomolar range (3.2-55 nM). A set of carboxylate derivatives demonstrated markedly improved in vitro metabolic stability (t1/2 > 2 h). A selected ligand showed significant in vivo efficacy with 73% of parasitemia reduction in a mouse model. Five new cocrystal structures with PvSHMT were solved at 2.3-2.6 ? resolution, revealing a unique water-mediated interaction with Tyr63 at the end of the para-Aminobenzoate channel. They also displayed the high degree of conformational flexibility of the Cys364-loop lining this channel.

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1)

The present invention is directed to 4,4-dl-substjtuted piperidine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1)

The present invention is directed to 4,4-di-substituted piperidine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

PIPERIDINE DERIVATIVE AND USE THEREOF

The present invention provides a novel piperidine derivative and a tachykinin receptor antagonist containing same, as well as a compound represented by the formula:wherein R1 is carbamoylmethyl, methylsulfonylethylcarbonyl and the like; R2 is methyl or cyclopropyl; R3 is a hydrogen atom or methyl; R4 is a chlorine atom or trifluoromethyl; R5 is a chlorine atom or trifluoromethyl; and a group represented by the formula:is a group represented by the formula:wherein R6 is a hydrogen atom, methyl, ethyl or isopropyl; R7 is a hydrogen atom, methyl or a chlorine atom; and R8 is a hydrogen atom, a fluorine atom, a chlorine atom or methyl; or 3-methylthiophen-2-yl, and a salt thereof.

UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES

This invention relates to a pharmaceutical comprising, as an active ingredient, a ureide derivative represented by formula: or a pharmaceutically acceptable salt thereof. The ureide derivative or a pharmaceutically acceptable salt thereof according to the present invention is useful for relieving pain and treating or preventing neuropathic pain.

PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS

A novel piperidine derivative represented by the formula (I) (I) wherein Ar is a phenyl group optionally having substituent(s), R?1? is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group or a heterocyclic group optionally having substituent(s), Z is a methylene group optionally having C?1-6#191 alkyl group(s), ring A is a piperidine ring optionally further having substituent(s), and B is a monocyclic aromatic heterocyclic group optionally having substituent(s) (substituents of monocyclic aromatic heterocycle may be bonded to each other to form a ring), or a salt thereof has a superior tachykinin receptor antagonistic action and the like, and is useful as an agent for the prophylaxis or treatment of lower urinary tract disease and the like.

PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.

PROTEASOME INHIBITORS AND METHODS OF USING THE SAME

The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

Aminopiperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.